Tapentadol
Keep the medication in a place where others cannot get to it. Taking opioid medicine during pregnancy may cause life-threatening withdrawal symptoms in the newborn. |
Tapentadol is a centrally acting analgesic with a dual mechanism of action of mu receptor agonism and norepinephrine reuptake inhibition. Tapentadol immediate-release is approved by the US Food and Drug Administration for the management of moderate-to-severe acute pain. |
Methods and analysis We evaluated key sources on pharmaceutical use and harms in Australia. |
Gregory R. Polston, Mark S. |
Background: This trial is part of the global pediatric clinical development program investigating the administration of the strong analgesic tapentadol in children and adolescents. Results: Sixty-six patients were treated. |
The undertreatment of acute pain is common in many health care settings. Insufficient management of acute pain may lead to poor patient outcomes and potentially life-threatening complications. |
Tapentadol is an opioid pain medication. |
Tapentadol SR is a centrally acting opioid analgesic that binds to the mu-opioid receptor. |
We weren't able to detect the audio language on your flashcards. Please select the correct language below. |
This medication also comes as an extended-release tablet that is taken usually twice daily with a tapentadol glass of hydrochloride. Common tapentadol effects of tapentadol are nausea, dizziness, and vomiting. |